http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 06:06:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/BeyondSpring+Inc.+%28BYSI%29+Reports+Q2+Loss+of+%240.02/26934203.html <p>BeyondSpring Inc. (NASDAQ: BYSI) reported Q2 EPS of ($0.02), versus $0.00 reported last year.</p><p>For earnings history and earnings-related data on BeyondSpring Inc. (BYSI) <a href="http://www.streetinsider.com/ec_earnings.php?q=BYSI">click here</a>.</p> http://www.streetinsider.com/Earnings/BeyondSpring+Inc.+%28BYSI%29+Reports+Q2+Loss+of+%240.02/26934203.html Mon, 17 Aug 2026 06:06:46 -0400 BYSI http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BeyondSpring+Inc.++++++++++++++++++++++Filed+by%3A+Huang+Lan/26932983.html si-local-file:///var/storage/secattach/20260814/26932983.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BeyondSpring+Inc.++++++++++++++++++++++Filed+by%3A+Huang+Lan/26932983.html Fri, 14 Aug 2026 17:34:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BeyondSpring+Inc.++++++++++++++++++++++Filed+by%3A+Huang+Lan/26932983.html si-local-file:///var/storage/secattach/20260814/26932983.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BeyondSpring+Inc.++++++++++++++++++++++Filed+by%3A+Huang+Lan/26932983.html Fri, 14 Aug 2026 17:34:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeyondSpring+Inc.+++++++++For%3A+Jun+30/26932823.html si-local-file:///var/storage/secattach/20260814/26932823.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeyondSpring+Inc.+++++++++For%3A+Jun+30/26932823.html Fri, 14 Aug 2026 17:21:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeyondSpring+Inc.+++++++++For%3A+Jun+30/26932823.html si-local-file:///var/storage/secattach/20260814/26932823.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeyondSpring+Inc.+++++++++For%3A+Jun+30/26932823.html Fri, 14 Aug 2026 17:21:00 -0400 BYSI O.31433175 http://www.streetinsider.com/Press+Releases/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html <p align="center">ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy</p> <p align="center">AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability</p> <p align="center">Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of the Confirmatory DUBLIN-4 Program in NSCLC Post-ICI and Long-Term Value Creation</p> <p>FLORHAM PARK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=dhglTRuYApnTEFneQH6w9IAb9dRiL86N_pLiXrU3uT1BU5sh1k6vQwEg8jYBZT7p-Dog4Ly9AvS6_sx4ML7wMIwQq_xMLggCmckF4ZbVibY=" rel="nofollow" target="_blank"><strong>BeyondSpring Inc.</strong></a> (NASDAQ: BYSI) http://www.streetinsider.com/Press+Releases/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/Press+Releases/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html <p align="center">ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy</p> <p align="center">AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability</p> <p align="center">Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of the Confirmatory DUBLIN-4 Program in NSCLC Post-ICI and Long-Term Value Creation</p> <p>FLORHAM PARK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=dhglTRuYApnTEFneQH6w9IAb9dRiL86N_pLiXrU3uT1BU5sh1k6vQwEg8jYBZT7p-Dog4Ly9AvS6_sx4ML7wMIwQq_xMLggCmckF4ZbVibY=" rel="nofollow" target="_blank"><strong>BeyondSpring Inc.</strong></a> (NASDAQ: BYSI) http://www.streetinsider.com/Press+Releases/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/Globe+Newswire/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html <p align="center">ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy</p> <p align="center">AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability</p> <p align="center">Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of the Confirmatory DUBLIN-4 Program in NSCLC Post-ICI and Long-Term Value Creation</p> <p>FLORHAM PARK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=dhglTRuYApnTEFneQH6w9IAb9dRiL86N_pLiXrU3uT1BU5sh1k6vQwEg8jYBZT7p-Dog4Ly9AvS6_sx4ML7wMIwQq_xMLggCmckF4ZbVibY=" rel="nofollow" target="_blank"><strong>BeyondSpring Inc.</strong></a> (NASDAQ: BYSI) http://www.streetinsider.com/Globe+Newswire/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/Globe+Newswire/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html <p align="center">ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy</p> <p align="center">AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability</p> <p align="center">Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of the Confirmatory DUBLIN-4 Program in NSCLC Post-ICI and Long-Term Value Creation</p> <p>FLORHAM PARK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=dhglTRuYApnTEFneQH6w9IAb9dRiL86N_pLiXrU3uT1BU5sh1k6vQwEg8jYBZT7p-Dog4Ly9AvS6_sx4ML7wMIwQq_xMLggCmckF4ZbVibY=" rel="nofollow" target="_blank"><strong>BeyondSpring Inc.</strong></a> (NASDAQ: BYSI) http://www.streetinsider.com/Globe+Newswire/BeyondSpring+Reports+Second-Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26932715.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Aug+14/26932728.html si-local-file:///var/storage/secattach/20260814/26932728.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Aug+14/26932728.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Aug+14/26932728.html si-local-file:///var/storage/secattach/20260814/26932728.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Aug+14/26932728.html Fri, 14 Aug 2026 17:15:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734592.html si-local-file:///var/storage/secattach/20260706/26734592.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734592.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734592.html si-local-file:///var/storage/secattach/20260706/26734592.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734592.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734594.html si-local-file:///var/storage/secattach/20260706/26734594.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734594.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734594.html si-local-file:///var/storage/secattach/20260706/26734594.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Qiu+Min/26734594.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Majeti+Jiangwen/26734595.html si-local-file:///var/storage/secattach/20260706/26734595.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Majeti+Jiangwen/26734595.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Majeti+Jiangwen/26734595.html si-local-file:///var/storage/secattach/20260706/26734595.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Majeti+Jiangwen/26734595.html Mon, 06 Jul 2026 13:10:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Li+Na+%28NL%29/26734582.html si-local-file:///var/storage/secattach/20260706/26734582.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Li+Na+%28NL%29/26734582.html Mon, 06 Jul 2026 13:09:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Li+Na+%28NL%29/26734582.html si-local-file:///var/storage/secattach/20260706/26734582.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BeyondSpring+Inc.+++++++++For%3A+Jul+01++Filed+by%3A+Li+Na+%28NL%29/26734582.html Mon, 06 Jul 2026 13:09:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26706889.html si-local-file:///var/storage/secattach/20260629/26706889.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26706889.html Mon, 29 Jun 2026 16:31:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26706889.html si-local-file:///var/storage/secattach/20260629/26706889.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26706889.html Mon, 29 Jun 2026 16:31:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26602462.html si-local-file:///var/storage/secattach/20260604/26602462.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26602462.html Thu, 04 Jun 2026 07:30:00 -0400 BYSI O.31433175 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26602462.html si-local-file:///var/storage/secattach/20260604/26602462.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeyondSpring+Inc.+++++++++For%3A+Jun+04/26602462.html Thu, 04 Jun 2026 07:30:00 -0400 BYSI O.31433175 http://www.streetinsider.com/Corporate+News/BeyondSpring+names+new+CEO+as+founder+transitions+to+chairman+role/26602346.html <p>BeyondSpring Inc. (NASDAQ: BYSI) announced a leadership transition effective July 1, 2026, with founder Dr. Lan Huang moving from CEO to Chairman while maintaining her role as CEO of SEED Therapeutics.</p><p>Min Qiu will become CEO with a mandate to execute the company's DUBLIN-4 confirmatory Phase 3 trial for Plinabulin in non-small cell lung cancer. Na Li was appointed Chief Financial Officer, and current director Dr. Jiangwen Majeti was named Vice Chairman.</p><p>The DUBLIN-4 trial will enroll 442 patients testing Plinabulin combined with docetaxel in non-squamous EGFR wild-type NSCLC patients who progressed on immune checkpoint inhibitor therapies. The study builds on DUBLIN-3 http://www.streetinsider.com/Corporate+News/BeyondSpring+names+new+CEO+as+founder+transitions+to+chairman+role/26602346.html Thu, 04 Jun 2026 07:01:33 -0400 BYSI http://www.streetinsider.com/Management+Changes/BeyondSpring+names+new+CEO+as+founder+transitions+to+chairman+role/26602346.html <p>BeyondSpring Inc. (NASDAQ: BYSI) announced a leadership transition effective July 1, 2026, with founder Dr. Lan Huang moving from CEO to Chairman while maintaining her role as CEO of SEED Therapeutics.</p><p>Min Qiu will become CEO with a mandate to execute the company's DUBLIN-4 confirmatory Phase 3 trial for Plinabulin in non-small cell lung cancer. Na Li was appointed Chief Financial Officer, and current director Dr. Jiangwen Majeti was named Vice Chairman.</p><p>The DUBLIN-4 trial will enroll 442 patients testing Plinabulin combined with docetaxel in non-squamous EGFR wild-type NSCLC patients who progressed on immune checkpoint inhibitor therapies. The study builds on DUBLIN-3 http://www.streetinsider.com/Management+Changes/BeyondSpring+names+new+CEO+as+founder+transitions+to+chairman+role/26602346.html Thu, 04 Jun 2026 07:01:33 -0400 BYSI